Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

Maximum days for report delivery for the Tissue Specific Breast Triple Negative Test by NGS is 14 days.

What are the prerequisites for the test Tissue Specific Breast Triple Negative Test by NGS

  • Must have a tissue sample from the breast
  • Must have a confirmed diagnosis of triple negative breast cancer
  • Must have a healthcare provider's order for the test
  • Must have signed informed consent for genetic testing

What are the measure values for the test Tissue Specific Breast Triple Negative Test by NGS

  • ERBB2 (HER-2) Copy Number: Negative (0-1.8)
  • ESR1 (ER) Mutations: Not Detected
  • PIK3CA Mutations: Not Detected
  • PTEN Mutations: Not Detected
  • TP53 Mutations: Not Detected

What does this test Tissue Specific Breast Triple Negative Test by NGS identify?

  • The Tissue Specific Breast Triple Negative Test by NGS identifies the presence of triple negative breast cancer in a tissue sample.
  • It uses Next Generation Sequencing (NGS) technology to analyze the DNA in the sample and detect specific mutations associated with triple negative breast cancer.
  • Triple negative breast cancer is a subtype of breast cancer that does not have receptors for estrogen, progesterone, or the HER2 protein.
  • Identifying triple negative breast cancer is important for determining the most effective treatment options, as this subtype does not respond to hormone-based therapies.

Why is this test Tissue Specific Breast Triple Negative Test by NGS taken?

Why is the Tissue Specific Breast Triple Negative Test by NGS taken?

The Tissue Specific Breast Triple Negative Test by NGS is taken to determine the genetic profile of a patient's breast cancer, specifically focusing on the triple negative subtype. Triple negative breast cancer is a subtype of breast cancer that lacks estrogen receptors, progesterone receptors, and HER2/neu protein overexpression. This test helps in identifying specific genetic mutations that may be driving the cancer, which can then be used to guide treatment decisions.

By analyzing the genetic makeup of the tumor using Next Generation Sequencing (NGS), healthcare providers can tailor treatment options to target the specific mutations present in the cancer cells. This personalized approach to treatment can lead to more effective therapies and better outcomes for patients with triple negative breast cancer.

No FAQs available.

Customer Google Rating